Strides Pharma Q2 FY27 consolidated PAT Rs 134.12 cr; revenue Rs 1,429.73 cr, +17.1% YoY
For Q2 FY27, Strides Pharma’s consolidated revenue from operations was Rs 1,429.73 cr and PAT Rs 134.12 cr versus Rs 1,220.83 cr and Rs 131.52 cr a year earlier.
Key takeaways
- Revenue from operations Rs 1,429.73 cr vs Rs 1,220.83 cr in Q2 FY26
- Total income Rs 1,433.82 cr vs Rs 1,247.97 cr in the year-ago quarter
- Total expenses Rs 1,282.58 cr vs Rs 1,085.03 cr a year earlier
- PAT Rs 134.12 cr vs Rs 131.52 cr in the corresponding quarter
- Basic and diluted EPS Rs 14.19 vs Rs 13.84 in Q2 FY26, not annualised
Q2 FY27 · consolidated
| Metric | Sep 2026 | Sep 2025 | Change |
|---|---|---|---|
| Revenue | Rs 1,429.73 cr | Rs 1,220.83 cr | +17.1% |
| PAT | Rs 134.12 cr | Rs 131.52 cr | +2.0% |
| EPS | Rs 14.19 | Rs 13.84 | +2.5% |
As reported in the filing. Figures are transcribed, not computed.
What the numbers show
- Net margin was 9.38% of revenue, down 139 bps from 10.77%.
- Total expenses rose 18.2% while revenue rose 17.1%.
- Cost of materials took 39.5% of revenue, against 35.2% a year earlier.
Key consolidated numbers (continuing operations, Q2 FY27 vs Q2 FY26)
From the statement of consolidated unaudited results for the quarter ended September 30, 2026, compared with the corresponding quarter ended September 30, 2025:
- Revenue from operations: Rs 1,429.73 cr (Q2 FY26: Rs 1,220.83 cr)
- Other income: Rs 4.08 cr (Q2 FY26: Rs 27.14 cr)
- Total income: Rs 1,433.82 cr (Q2 FY26: Rs 1,247.97 cr)
- Cost of materials consumed: Rs 564.95 cr (Q2 FY26: Rs 429.76 cr)
- Purchases of stock-in-trade: Rs 180.97 cr (Q2 FY26: Rs 41.80 cr)
- Changes in inventories of finished goods, work-in-progress and stock-in-trade: Rs (116.49) cr (Q2 FY26: Rs 43.70 cr)
- Employee benefits expense: Rs 238.27 cr (Q2 FY26: Rs 226.78 cr)
- Finance costs: Rs 46.54 cr (Q2 FY26: Rs 46.13 cr)
- Depreciation and amortisation expense: Rs 57.22 cr (Q2 FY26: Rs 49.64 cr)
- Other expenses: Rs 311.12 cr (Q2 FY26: Rs 247.22 cr)
- Total expenses: Rs 1,282.58 cr (Q2 FY26: Rs 1,085.03 cr)
- Profit before exceptional items and tax: Rs 151.24 cr (Q2 FY26: Rs 162.94 cr)
- Exceptional items: Rs (1.70) cr (Q2 FY26: Rs (8.77) cr)
- Profit before tax (after exceptional items): Rs 149.54 cr (Q2 FY26: Rs 154.16 cr)
- Share of profit/(loss) of joint venture and associates, net of taxes – (net): Rs 0.899 cr (Q2 FY26: Rs (1.05) cr)
- Profit before tax (after JV/associates): Rs 150.44 cr (Q2 FY26: Rs 153.12 cr)
- Total tax expense: Rs 16.32 cr (Q2 FY26: Rs 21.59 cr)
- Profit for the period (PAT): Rs 134.12 cr (Q2 FY26: Rs 131.52 cr)
- Basic EPS (Rs, not annualised): Rs 14.19 (Q2 FY26: Rs 13.84)
- Diluted EPS (Rs, not annualised): Rs 14.19 (Q2 FY26: Rs 13.84)
In Q2 FY27, consolidated revenue from operations and total income increased versus the same quarter last year, as shown in the statement of financial results. Total expenses also rose, with higher cost of materials consumed, purchases of stock-in-trade and other expenses compared with the corresponding quarter ended September 30, 2025.
Profit before exceptional items and tax for the quarter was lower than in the year-ago period, while exceptional items in both quarters were reported as negative figures in the statement of consolidated unaudited results. After accounting for the share of profit/(loss) of joint venture and associates and tax expense, profit for the period (PAT) was slightly higher year-on-year. Basic and diluted earnings per share (not annualised) also increased compared with the corresponding quarter of the previous year, based on the figures disclosed in the statement of financial results.
Track Strides Pharma Science Ltd
Cruxal reads every Strides Pharma Science Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Get every filing that moves a stock
One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.
Cruxal publishes market coverage for information only. Nothing here is investment advice.
